Moderna 2026 Covid and RSV growth not enough to boost stock, Jefferies says

Moderna Inc (NASDAQ:MRNA, XETRA:0QF) has been awarded a ‘Hold' rating and $30 price target, implying limited upside, from Jefferies analysts in their initial coverage of the drugmaker. Moderna shares are down almost 28% in the year to date, trading just shy of $30 on Friday morning.

Proactive Investors • Dec 12, 2025

Moderna (MRNA) Just Reclaimed the 200-Day Moving Average

From a technical perspective, Moderna (MRNA) is looking like an interesting pick, as it just reached a key level of support. MRNA recently overtook the 200-day moving average, and this suggests a long-term bullish trend.

Zacks Investment Research • Dec 8, 2025

Moderna (MRNA) Recently Broke Out Above the 50-Day Moving Average

Moderna (MRNA) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, MRNA broke through the 50-day moving average, which suggests a short-term bullish trend.

Zacks Investment Research • Dec 8, 2025

Moderna (MRNA) Recently Broke Out Above the 20-Day Moving Average

Moderna (MRNA) is looking like an interesting pick from a technical perspective, as the company reached a key level of support. Recently, MRNA crossed above the 20-day moving average, suggesting a short-term bullish trend.

Zacks Investment Research • Dec 4, 2025

Moderna, Inc. (MRNA) Presents at Piper Sandler 37th Annual Healthcare Conference Transcript

Moderna, Inc. (MRNA) Presents at Piper Sandler 37th Annual Healthcare Conference Transcript

Seeking Alpha • Dec 2, 2025

Vaccine Stocks Fall After FDA Plans to Impose Stricter Vaccine Rules

Shares of vaccine makers slide as an internal FDA memo on vaccine safety and plans for stricter rules spark broad pressure across the overall industry.

Zacks Investment Research • Dec 2, 2025

Moderna stock slides as FDA moves to tighten vaccine guidelines

Moderna Inc (NASDAQ:MRNA, XETRA:0QF) stock fell sharply on the news that the Food and Drug Administration (FDA) plans to implement stricter approval requirements for vaccines. The announcement raised investor concerns about potential delays and increased scrutiny for the company's pipeline of new products.

Proactive Investors • Dec 1, 2025

Vaccine stocks take a hit as FDA official points to link between COVID-19 vaccines and rare heart condition in young men

Memo also reportedly mentions vaccines for flu and pneumonia.

Market Watch • Dec 1, 2025

Top Stock Movers Now: Coinbase, Robinhood, Moderna, Synopsys, and More

Major U.S. equities indexes lost ground Monday afternoon, as shares of tech and cryptocurrency-related companies pulled back. The S&P 500 and Nasdaq slid about 0.2%, while the Dow dropped 0.4%.

Investopedia • Dec 1, 2025

FDA Plans to Tighten Vaccine Approvals Weigh on These Stocks

A report that vaccine approvals could be set to get stricter is pressuring shares of major vaccine makers.

Investopedia • Dec 1, 2025